Category - News

Developments

Tonix starts Phase 2 intranasal oxytocin study in chronic migraine

Tonix Pharmaceuticals (NASDAQ:TNXP) enrolled the first participant in the Phase 2 PREVENTION study of TNX-1900 (intranasal potentiated oxytocin) for the prevention of chronic migraine headache. The double-blind, placebo...

February 6, 2023

Markets

Cantor starts Outlook Therapeutics at OW; PT $4

Cantor Fitzgerald launched coverage of Outlook Therapeutics (NASDAQ:OTLK) with an “overweight” rating and a 12-month price target of $4. The stock closed at $1.15 on Feb. 3. Outlook is a biopharmaceutical company that...

February 6, 2023

Developments

Theralase to present Phase 2 NMIBC interim data at AUA meeting

The American Urology Association has accepted for a moderated poster presentation at its annual meeting Theralase Technologies’ (TSXV:TLT; OTCQB:TLTFF) interim data from its Phase 2 Bacillus Calmette Guerin unresponsive...

February 2, 2023

Developments

Miromatrix to respond to FDA clinical hold on miroliverELAP in second half

Miromatrix Medical (NASDAQ:MIRO) has evaluated a clinical hold on its investigational miroliverELAP transplantable organ and plans to submit its response to the FDA in the second half of 2023 and initiate a first-in...

February 1, 2023

Developments

Roth Capital acquires MKM Partners

Roth Capital Partners completed its acquisition of MKM Partners on Jan. 31, and the combined organization will conduct business as ROTH MKM. This is the first acquisition ROTH has made in its 30-plus years of business...

February 1, 2023

Markets

Brookline analyst assumes coverage of Hepion at buy; PT $4

Brookline Capital Partners analyst Kemp Dolliver assumed coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and $4 price target. The stock finished at 73 cents on Jan. 31. Hepion’s rencofilstat is a...

February 1, 2023

Markets

AGP starts Hepion at buy; PT $4

Alliance Global Partners launched coverage of Hepion Pharmaceuticals (NASDAQ:HEPA) with a “buy” rating and price target of $4. Shares of Hepion closed at 73 cents on Jan. 31. Analyst James Molloy writes that his...

February 1, 2023

Markets

Cantor starts Editas Medicine at OW; PT $15

Cantor Fitzgerald initiated coverage of Editas Medicine (NASDAQ:EDIT) with an “overweight” rating and 12-month price target of $15. The stock closed at $9.35 on Jan. 31. Editas is a clinical-stage gene editing company...

February 1, 2023

Developments

First Wave to initiate Phase 2 trial of enhanced adrulipase formulation

First Wave BioPharma (NASDAQ:FWBI) plans to initiate a Phase 2 clinical trial of an enhanced enteric microgranule delivery formulation of adrulipase for the treatment of exocrine pancreatic insufficiency (EPI) in...

January 31, 2023

Developments

Reneo receives FDA fast track for of long-chain fatty acid oxidation disorder

The FDA granted Reneo Pharmaceuticals’ (NASDAQ:RPHM) mavodelpar (REN001) fast track designation for long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD) deficiency, one of the predominant genotypes in patients with long...

January 31, 2023

Category - News

Subscribe